Janoshik, Jano, BAC water, 503A, LegitScript, reta, LY3437943, endotoxin, COA. The gray-market peptide community speaks a specific dialect, and the legitimate-care side has its own. Here’s what every term means and why it matters.
A Czech analytical lab widely used by the gray-market peptide community for HPLC purity and mass-spectrometry identity testing. Issues unique sample IDs verifiable at janoshik.com/verify. Not ISO 17025 accredited. Does not test for sterility, endotoxin, heavy metals, residual solvents, or stereochemistry. Read about Janoshik COA fraud →
A document issued by a testing lab summarizing analytical results for a specific sample. In the gray-market peptide community, vendor-supplied COAs are routinely forged, recycled across products, or unverifiable through the issuing lab’s portal. Modern Peptides was caught with a forged NAD+ COA where the actual Janoshik test on file was for QSC bacteriostatic water.
An analytical chemistry technique that separates and quantifies the components of a peptide sample. Provides purity percentage and a chromatogram. Standard test on a Janoshik COA. Does not test for sterility, endotoxin, or stereochemistry — the things that send people to the ER.
The standard pharmaceutical test for bacterial endotoxin contamination, using a clotting agent extracted from horseshoe crab blood. Required under USP standards for injectable pharmaceuticals. Not run by Janoshik or most gray-market peptide testing labs.
Bacterial cell-wall fragments released when Gram-negative bacteria die. Injecting endotoxin causes fever, septic shock, hypotension, and severe injection-site reactions. Found in 100% of gray-market semaglutide samples in the 2024 JMIR study.
The international standard for the competence of testing and calibration laboratories. Accredited labs operate under documented quality-management systems and proficiency testing. Most gray-market peptide testing labs (including Janoshik) are not ISO 17025 accredited.
The FDA’s public database of adverse event reports for drugs and therapeutic biologics. Searchable at faers.fda.gov. Tracks deaths, hospitalizations, and serious adverse events including those linked to compounded and gray-market GLP-1 peptides.
A form FDA inspectors issue to a regulated facility documenting observed deviations from federal requirements. Not a citation in itself, but the precursor to enforcement action. The MedisourceRx Form 483 (March 2026) documented a live spider in the compounding room of Hims’s compounded-semaglutide partner.
A US pharmacy licensed to compound individualized medications for specific patients with valid prescriptions. Regulated by state boards of pharmacy under Section 503A of the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act of 2013. Most LegitScript-certified compounded telehealth providers source from 503A pharmacies.
A US compounding facility that produces compounded medications in larger quantities for hospitals and clinics. Registers with the FDA, submits to FDA inspection, and operates under cGMP-like standards. Created by Section 503B of the FD&C Act after the 2012 New England Compounding Center contamination outbreak.
An independent regulatory monitoring and certification service for healthcare merchants. LegitScript-certified telehealth providers and compounding pharmacies have been verified for state licensing, prescription protocols, and pharmacy partnerships. Verifiable at legitscript.com. Eden Health, Enhance MD, bmiMD, Get Thin MD, Breeze Meds, and Sprout Health are all LegitScript-certified.
Maintains the .pharmacy verified-domain program and an accredited online-pharmacy directory at nabp.pharmacy. Operates the NABP Digital Pharmacy Accreditation program. Use NABP’s public lookup to verify any pharmacy claim before signing up.
The non-profit organization that establishes quality standards for medicines, dietary supplements, and food ingredients in the US. USP standards include identity, strength, purity, sterility, and residual-solvent specifications that legitimate pharmaceutical compounding must meet.
A GLP-1 receptor agonist developed by Novo Nordisk. FDA-approved for type 2 diabetes (Ozempic injection, Rybelsus oral) and chronic weight management (Wegovy injection). The most-counterfeited GLP-1 on the gray market.
A dual GIP/GLP-1 receptor agonist developed by Eli Lilly. FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). LillyDirect sells Zepbound vials at $299/mo manufacturer-direct.
Eli Lilly’s investigational triple-agonist (GLP-1, GIP, and glucagon receptor) for obesity and type 2 diabetes. Compound code LY3437943. Currently in Phase 3 trials (the TRIUMPH program). Not FDA-approved as of 2026. No legal source exists in the US outside clinical-trial participation. See the retatrutide FAQ →
An amylin analog developed by Novo Nordisk, often paired with semaglutide in trials (the “CagriSema” combination). Different mechanism, different dosing, different safety profile from semaglutide. Coastal Peptides was caught selling cagrilintide labeled as semaglutide.
An incretin hormone receptor. Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds glucagon receptor activation on top of GIP and GLP-1 for triple-agonist activity. The receptor combination is what differentiates the three major GLP-1-class drugs.
Salt forms chemically distinct from the FDA-approved base forms used in Wegovy and Zepbound. Have not been tested in humans. Some gray-market vendors and unauthorized compounding operations use these salt forms, which the FDA has explicitly flagged as outside the legal compounding framework.
Sterile water containing 0.9% benzyl alcohol as a preservative, used to reconstitute lyophilized (freeze-dried) peptides. Distinct from sterile water for injection (no preservative). Reconstitution with the wrong water source — tap water, distilled water, or non-sterile saline — is a common contamination vector in DIY peptide preparation.
Freeze-dried. Lyophilized peptides are sold as a powder that must be reconstituted with bacteriostatic water before injection. More stable in transit than reconstituted solutions but still requires cold-chain storage for long-term integrity.
The temperature-controlled supply chain required for biologic medications. GLP-1 peptides require continuous storage at 2 to 8 degrees Celsius. Legitimate pharmacy fulfillment uses refrigerated overnight shipping with documented temperature monitoring; gray-market shipments typically transit 10 to 45 days at ambient temperature without monitoring.